Back to top
more

Harmony Biosciences (HRMY)

(Delayed Data from NSDQ)

$34.40 USD

34.40
726,870

-0.78 (-2.22%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 23.44% and 1.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Harmony Biosciences (HRMY) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

HRMY or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Harmony Biosciences (HRMY) Stock

by Zacks Equity Research

Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Harmony Biosciences (HRMY) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 600% and 0.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HRMY or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts See a 32.82% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 32.8% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Rimmi Singhi headshot

5 High Earnings Yield Value Stocks That You Shouldn't Ignore

by Rimmi Singhi

Unlock your portfolio value by investing in stocks like HRMY, GPRK, GCT, CMRE and ARKO to fetch handsome returns.

Zacks Equity Research

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice

by Zacks Equity Research

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

HRMY or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

HRMY vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRMY vs. TECH: Which Stock Is the Better Value Option?